The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Bronchiolitis

Bronchiolitis

Bronchiolitis is a common respiratory disorder, primarily affecting young children, that is characterized by inflammation and obstruction of the small airways (bronchioles).
It is often caused by viral infections, such as respiratory syncytial virus (RSV), and can lead to symptoms like coughing, wheezing, and difficulty breathing.
Proper diagnosis and management of Bronchiolitis are crucial for ensuring the best possible outcomes for patients.
This MeSH term provides a concise overview of this important medical condition.

Most cited protocols related to «Bronchiolitis»

We conducted a multicenter prospective cohort study of infants (age <1 year) hospitalized for bronchiolitis (severe bronchiolitis). This study, called the 35th Multicenter Airway Research Collaboration (MARC-35) (17 ), was coordinated by the Emergency Medicine Network (EMNet)(18 ), a collaboration of 235 participating hospitals.
Using a standardized protocol, site investigators at 17 sites across 14 U.S. states (Table E1 in the Online Supplement) enrolled infants hospitalized with an attending physician diagnosis of bronchiolitis during three consecutive bronchiolitis seasons from November 1 to April 30 (2011-2014). Bronchiolitis was defined by the American Academy of Pediatrics guidelines – acute respiratory illness with some combination of rhinitis, cough, tachypnea, wheezing, crackles, and retractions (19 (link)). We excluded infants with previous enrollment, those who were transferred to a participating hospital >24 hours after the original hospitalization, those who were consented >24 hours after hospitalization, or those with known heart-lung disease, immunodeficiency, immunosuppression, or gestational age <32 weeks. All patients were treated at the discretion of the treating physician. The institutional review board at each of the participating hospitals approved the study. Written informed consent was obtained from the parent or guardian.
Publication 2016
Bronchiolitis CCL7 protein, human Cor Pulmonale Cough Diagnosis Dietary Supplements Ethics Committees, Research Gestational Age Hospitalization Immunologic Deficiency Syndromes Immunosuppression Infant Legal Guardians Parent Patients Physicians Respiratory Rate Rhinitis
All analyses were performed using Stata 11.2 (Stata Corp, College Station, TX). Data are presented as proportions with 95% confidence intervals (95%CIs) and medians with interquartile ranges (IQR). Our primary analyses focused on RSV and HRV, the most commonly detected viruses in children with severe bronchiolitis. For the purposes of this analysis we combined RSV-A with RSV-B since the clinical distinction between the two subtypes of RSV was unremarkable. For analyses, we created a categorical variable that reflected the possible combinations of RSV/HRV status: (1) RSV only infection, (2) HRV only infection, (3) RSV in combination with HRV, (4) RSV in combination with non-HRV pathogens, and (5) HRV in combination with non-RSV pathogens.
We performed univariate analyses using chi-square, and Fisher’s exact test, and Kruskall Wallis test, as appropriate. All P-values were two-tailed, with P<0.05 considered statistically significant. Multivariable logistic regression analyses were conducted to evaluate independent predictors of longer LOS (≥3 days; defined using the median value of 2 days) and other measures of severity: ICU admission and continuous positive airway pressure (CPAP)/intubation. Factors were selected for inclusion in the model if they were found to be associated with the outcome in unadjusted analyses (P<0.20) or were potentially clinically significant. All regression models account for potential clustering by site. To further investigate independent predictors of LOS, a zero-truncated negative binomial model was also used to evaluate the relationship between demographic and clinical factors and LOS in days (continuous outcome). Children who were hospitalized for <1 day were assigned 0.5 days LOS. Results of the zero-truncated negative binomial model are reported as incidence rate ratios (IRRs) with 95%CIs.
Publication 2012
Bronchiolitis Child Continuous Positive Airway Pressure Infection Intubation pathogenesis Respiratory Syncytial Virus Infections Virus
We systematically reviewed all literature published from January 1, 1990 through March 31, 2012 to identify studies with data on risk factors for pediatric pneumonia. We searched a variety of databases-Medline (Ovid), Embase, CINAHL and Global Health Library using combinations of key search terms: pneumonia, low birth weight, undernutrition, breast feeding, crowding, smoking, indoor air pollution, immunization, HIV etc. (full search terms are available in Supplementary material). Hand searching of online journals was also performed by examining the reference lists for relevant articles. We did not apply any language or publication restrictions. Relevant full-text articles in foreign language were translated to English using Google translator.
We defined an episode of severe pneumonia in hospital setting as any child hospitalized overnight with an admission diagnosis of pneumonia or bronchiolitis. In community-based studies, the presence of lower chest wall indrawing in a child with cough and difficulty breathing with increased respiratory rate for age was used to define a case, using the same cut off values as in the WHO's case definition (4 ,5 ). We recognized that the eligible studies used varying case definitions for the putative risk factors. We therefore grouped the risk factor definitions into categories and analyzed the association between risk factor and outcome for each of these categories (Table 1). We classified the risk factors into three groups based on the consistency and strength of association with severe ALRI:
(i) those that consistently (ie, across all identified studies) demonstrated an association with severe ALRI, with a significant meta-estimate of the odds ratio, would be classified as “definite”;
(ii) those demonstrating an association in the majority (ie, in more than 50%) of studies, with a meta-estimate of the odds ratio that was not significant, would be classified as “likely;” and
(iii) those that were sporadically (ie, occasionally) reported as being associated with severe ALRI in some contexts were classified as “possible.” This classification is consistent with the one originally used by Rudan et al (2 (link)).
We included studies that reported severe pneumonia in children under five years of age (Table 2). Eligible study designs included randomized control trials (RCTs), observational studies (cohort, case-control, or cross-sectional) that assessed the relationship between severe pneumonia in children and any one of the putative risk factors. Studies were excluded if their sample size was less than 100 detected cases, if their case definitions did not meet our broad range of case definitions, or if the case definitions were not stated clearly and/or not consistently applied (Figure 1). Studies where health care workers went house to house to identify cases of pneumonia were considered as having active community-based case ascertainment. By contrast, studies where children with pneumonia presented to a health facility were considered as having passive hospital-based case ascertainment.
The included studies used either multivariate or univariate analyses to report the association between the putative risk factors and the outcome, ie severe pneumonia. Since the multivariate design takes into account the interaction with other risk factors and potential confounders, we decided to report the results of the meta-analysis of these data separately. We decided that if there was significant heterogeneity in the data, ie, I2>80%, (corresponding to P < 0.005) (6 (link)), then we would report the meta-estimates from the random effects model (7 (link)). Importantly, we hypothesized that the effects of the risk factors were likely to be different in developing countries and industrialized countries. Because of this, we decided to report the results separately for developing (Table 3) and industrialized countries (Table 4). We extracted all relevant information from each retained study (Supplementary Table S2(supplementary Table 2)) and assessed the quality of included studies using a modified GRADE scoring system (Supplementary Tables S1(supplementary Table 1)) (8 (link)). Briefly, we assessed each article against the GRADE criteria and calculated the overall score for each article. We then calculated the cumulative score for each risk factor after accounting for the included studies (Supplementary Table S3(supplementary Table 3)). We used Stata 11.2 (StataCorp, College Station, TX, USA) for the meta-analysis (Figure 2; Supplementary Figure S1(supplementary Figure 1)).
Full text: Click here
Publication 2013
Air Pollution, Indoor Bronchiolitis cDNA Library Child Cough Diagnosis Genetic Heterogeneity Health Personnel Immunization Malnutrition Pneumonia Population at Risk Wall, Chest
We conducted a prospective, multicenter cohort study for 3 consecutive years during the 2007 to 2010 winter seasons, as part of the Multicenter Airway Research Collaboration (MARC), a program of the Emergency Medicine Network (EMNet) (www.emnet-usa.org). The number of participating sites varied over the 3 years: 13 sites in year 1; 16 sites in year 2; and 14 sites in year 3. Each month from November 1 until March 31, site investigators across 12 US states used a standardized protocol to enroll a target number of consecutive patients from the inpatient wards and the intensive care unit (ICU). Once the site reached their target enrollment for that month, the investigators would stop enrollment until the beginning of the following month.
All patients were treated at the discretion of the treating physician. Inclusion criteria were an attending physician’s diagnosis of bronchiolitis, age <2 years, and the ability of the parent/guardian to give informed consent. The exclusion criterion was previous enrollment. All consent and data forms were translated into Spanish. The institutional review board at each of the 16 participating hospitals approved the study.
Publication 2012
Bronchiolitis Diagnosis Ethics Committees, Research Hispanic or Latino Inpatient Legal Guardians Parent Patients Physicians
We performed a retrospective descriptive data analysis based on the data derived from ICD‐10‐based influenza and other ARI surveillance systems SEEDARE and ICOSARI, and from the virological surveillance at the RKI. The SEEDARE system has functioned since 2007, the virological surveillance since 2010, and ICOSARI since 2015. The datasets of ICOSARI for the years 2009 to 2014 were collected retrospectively. The Appendix S1 provides details on the surveillance participants, data collection methods, collected data, total number of collected data, and study period (13, 14, 15, Appendix S1).
The SEEDARE system was approved by the German Federal Commissioner for Data Protection and Freedom of Information, and the ICOSARI system by the RKI and HELIOS Kliniken GmbH data protection authority. As SEEDARE and ICOSARI involved no interventions and the analysis was based on anonymized data only, no ethical clearance was required for them.14, 15 The virological surveillance activities were approved by the German Federal Commissioner for Data Protection and Freedom of Information and the Ethical Committee of the Charité, Universitätsmedizin, Berlin.
We defined a RSV‐ICD‐case based on SEEDARE data as a medical consultation with any of the three RSV‐specific ICD‐10 code diagnoses (J12.1 RSV pneumonia, J20.5 acute bronchitis due to RSV, and J21.0 acute bronchiolitis due to RSV).6 We defined a RSV‐ICD‐case based on ICOSARI data as a hospitalization with any of the three RSV‐specific ICD‐10 code diagnoses as primary discharge diagnosis. In the virological surveillance, we defined a confirmed‐RSV‐case as a by real‐time reverse transcriptase polymerase chain reaction (rtRT‐PCR) confirmed RSV sample. In each data source, a RSV season was defined as the weeks when cumulative number of RSV‐ICD‐cases or confirmed‐RSV‐cases exceeded 1.2% of total RSV‐ICD‐cases or confirmed‐RSV‐cases. One gap week below the threshold was allowed.20, 21We estimated number of RSV‐ICD‐cases and confirmed‐RSV‐cases by gender, age group (0‐1, 2‐4, 5‐14, 15‐34, 35‐49, 50‐59, ≥60 years), and calendar week based on each data source, respectively.
We identified the sentinel practices that participated in both SEEDARE and the virological surveillance concurrently by practice‐ID. We matched the medical consultations of SEEDARE with virological samples by practice‐ID, age, gender, consultation date, and sampling date. Only one‐to‐one matches were included for the further data evaluation. We calculated sensitivity of RSV‐specific ICD‐10 code diagnosis as proportion of RSV‐ICD‐cases among confirmed‐RSV‐cases, and specificity as proportion of non‐RSV‐ICD‐cases among non‐confirmed‐RSV‐cases of the identified practices. We calculated sensitivity and specificity of RSV‐specific ICD‐10 code diagnosis among young children, in RSV seasons, and combined with different general ARI ICD‐10 codes J06.‐ acute upper respiratory infections of multiple and unspecified sites (J06, J06.0, J06.8, J06.9), J11.‐ influenza, virus not identified (J11, J11.0, J11.1, J11.8), J12.‐ viral pneumonia, not elsewhere classified (J12, J12.8, J12.9), J18.‐ pneumonia, organism unspecified (J18, J18.0, J18.8, J18.9), J20.‐ acute bronchitis (J20, J20.8, J20.9), J21.‐ acute bronchiolitis (J21, J21.8, J21.9), J22 unspecified ALRI, and B34.9 unspecified viral infection, respectively.6 The sensitivities and specificities were calculated with 95% confidence interval (95%‐CI). Additionally, we compared RSV‐ICD‐cases with confirmed‐RSV‐cases of the identified practices by calendar week.
We used Stata (version 15) and microsoft excel 2010 for the data analysis.
Full text: Click here
Publication 2019
Age Groups Bronchiolitis Bronchitis Child Diagnosis Hospitalization Hypersensitivity Influenza Patient Discharge Pneumonia Pneumonia, Viral Reverse Transcriptase Polymerase Chain Reaction Upper Respiratory Infections Virus Virus Diseases

Most recents protocols related to «Bronchiolitis»

Example 14

In contrast to the previous experimental infection using specific pathogen-free Beagles (Crawford et al., 2005), the virus-inoculated mongrel dogs had pneumonia as evidenced by gross and histological analyses of the lungs from days 1 to 6 p.i. In addition to pneumonia, the dogs had rhinitis, tracheitis, bronchitis, and bronchiolitis similar to that described in naturally infected dogs (Crawford et al., 2005). There was epithelial necrosis and erosion of the lining of the airways and bronchial glands with neutrophil and macrophage infiltration of the submucosal tissues (FIG. 5, upper panels). Immunohistochemistry detected viral H3 antigen in the epithelial cells of bronchi, bronchioles, and bronchial glands (FIG. 5, lower panels). No bacterial superinfection was present. The respiratory tissues from the 2 sham-inoculated dogs were normal.

Full text: Click here
Patent 2024
Antigens, Viral Autopsy Bacteria Bronchi Bronchioles Bronchiolitis Bronchitis Canis familiaris Epithelial Cells Immunohistochemistry Infection Lung Macrophage Necrosis Neutrophil Pneumonia Respiratory Rate Rhinitis Specific Pathogen Free Superinfection Tissues Tracheitis Virus
This is a retrospective, observational, cross‐sectional study conducted at the PED of “Fondazione Policlinico A. Gemelli - IRCCS” in Rome, a university third level Italian hospital with annual attendance of about 15,000 patients. We selected records - stored in the electronic Emergency Department information system (Gipse®) - of patients aged from 0 to 2 years admitted to PED with diagnosis of “acute bronchiolitis”, “wheezing”, “respiratory distress” and “acute respiratory failure”. Children older than 2 years and those with previous episodes of bronchiolitis were excluded. The collected data included: age, gender, hospital triage code, prematurity and/or other comorbidities (such as bronco-pulmonary dysplasia, asthma, atopy, genetic syndromes), pediatric clinical history, modality of transport to the PED, hospitalization (ward or Pediatric intensive Care Unit (PICU)) and etiology. Hospital triage codes were assigned to patients by the triage nurse based on the child’s general condition, symptoms and vital signs. The 5-code system, used in our region, included the assignment of code 1 for “emergency”, 2 for “urgency”, 3 for “deferable urgency”, 4 for “minor urgency” and 5 for “non-urgent” cases. For the statistical analysis we grouped patients with 1, 2 and 3 codes in the “high priority” group and those with 4 and 5 codes in the “low priority” group.
Therefore, we analyzed data of all children diagnosed with bronchiolitis admitted to our PED between September 2021 and March 2022 (post-COVID period), comparing them to those admitted during the same months in 2020-2021 (COVID period), in 2018-2019 and 2019-2020 (pre-COVID period). In addition, during COVID and post-COVID period nasopharyngeal swabs for the identification of SARS-CoV-2 were obtained from all children admitted in the PED. In some cases, a real-time reverse-transcriptase polymerase chain reaction for the detection of Rhinovirus, RSV, Influenza A and B, Parainfluenza virus, Human metapneumovirus and other Coronaviruses was performed. The study protocol was approved by the Institutional Review Board and Ethics Committee of our institution.
Publication 2023
Asthma Bronchiolitis Child Coronavirus Emergencies Ethics Committees, Research Gender Hereditary Diseases Hospitalization Human Metapneumovirus Influenza Inpatient Institutional Ethics Committees Lung Nasopharynx Nurses Parainfluenza Patients Premature Birth Real-Time Polymerase Chain Reaction Respiratory Failure Respiratory Rate Rhinovirus A RNA-Directed DNA Polymerase SARS-CoV-2 Signs, Vital Virus
To estimate the proportion of influenza-attributable SARI, a periodic regression method was applied to the weekly number of hospitalizations for pneumonia and bronchitis [7 (link)]. We modelled the baseline level with a multivariable linear regression model using the following equation:
where yw is, for week w, the number of pneumonia and bronchitis hospitalizations.
The baseline level in a given week w was obtained by fitting the model to the observations from 1/07/2012 to 30/06/2018 from which we removed the presence of influenza and bronchiolitis epidemics (Additional file 1) in the training dataset from the series. This trimming was an attempt to ensure that the dataset used to model the baseline level was free of influenza or respiratory syncytial virus (RSV) [8 (link)].
The number of excess hospitalizations for pneumonia or bronchitis was defined as the sum of the differences between the expected and observed values. This excess was considered attributable to influenza during periods defined as influenza epidemics.
Full text: Click here
Publication 2023
Bronchiolitis Bronchitis Epidemics Hospitalization Human respiratory syncytial virus Pneumonia Virus Vaccine, Influenza
We also performed a generalized linear model (GLM) as a complementary approach to validate the results of the periodic regression method. Specifically, the GLM was performed to estimate the number of influenza-associated hospitalizations during the epidemic periods by using overall pneumonia and bronchitis (PD) hospitalizations, assuming negative-binomial distributed errors with a logarithmic link function.
Two model parameters were used: indicators of influenza activity (including influenza-like illness (ILI) incidence data and virological data), and morbidity data for RSV. Weekly ILI incidence data were obtained from the French general practitioner network Sentinelles. Percentages of nasopharyngeal samples testing positive for influenza in France were obtained from the National Reference Center for Influenza. Swabs were performed by practitioners in the Regional Groups for Influenza Surveillance Network (GROG) (until the 2013/2014 influenza season) and by members of the Sentinelles network (from the 2014/2015 influenza season onward). These data were stratified by influenza type and subtype: A(H1N1)pdm09, A(H3N2) and B. For each influenza type and subtype, the product of ILI incidence and the percentage of samples testing positive was used as an indicator of influenza activity. As a proxy for the circulation of RSV, the proportions of consultations for bronchiolitis were obtained from computerized medical records completed during consultations at emergency departments participating in the OSCOUR® network (representing from approximatively 50% of national emergency department activity in 2010-11 to 90% in 2016-17). Model parameters are described in Additional file 2.
The GLM model analysis could only be performed on the five seasons from 2013 to 14 to 2017-18 because of the lack of availability of virological data for influenza before 2013.
The model was adjusted for temporal trend and RSV circulation. We selected lags on influenza activity indicators (lags retained: 0, 1) and the RSV indicator (lags 0, 1), based on the Akaike Information Criterion (AIC). In order to take into account the nonlinear relationship between hospitalizations for pneumonia and bronchitis and covariables, we used b-splines (with three degrees of freedom) on each component [9 (link)]. Population figures were introduced into the model as an offset.
The following regression model was used:
where was the number of pneumonia and bronchitis hospitalizations predicted by the model, was the offset corresponding to the population size, was the time, a function of b-splines with three degrees of freedom, and a function of lag.
The number of pneumonia and bronchitis hospitalizations attributable to influenza was estimated as the difference between the number predicted by the model and the number predicted by the model in the absence of influenza virus circulation. The numbers of weekly pneumonia and bronchitis hospitalizations attributable to influenza estimates were summed to obtain estimates during the five epidemic periods.
Full text: Click here
Publication 2023
Bronchiolitis Bronchitis Epidemics Hospitalization Nasopharynx Orthomyxoviridae Pneumonia Virus Vaccine, Influenza
We retrospectively collected data (gender, gestational age, birthweight, age and weight at admission, need for non-invasive or invasive respiratory support, need for intravenous infusion, need for enteral fasting) from the medical records of neonates and infants aged <3 months, admitted to the Neonatal Intensive Care Unit and Neonatal Sub-Intensive Care Unit of our hospital for bronchiolitis from October 2021 to March 2022. We calculated clinical severity scores (WBSS, KRS, and eventually GRSS for patients with RSV infection only) on admission clinical data. Table 1 shows the parameters of each score. The WBSS consists of four items (respiratory rate, general appearance, wheezing, retractions), each ranging from 0 to 3, except for the general condition, which is scored only 0 and 3, with a total from 0 to 12. The KRS is based on five signs (respiratory rate, general appearance, wheezing, retractions and skin color), each from 0 to 2, with a total from 0 to 10. The GRSS is calculated entering ten parameters (age, oxygen saturation, respiratory rate, general appearance, wheezing, rhales/ronchi, retractions, skin color, lethargy, and poor air movement) in an interactive tool (available at: https://rprc.urmc.rochester.edu/app/AsPIRES/RSV-GRSS/).
We excluded infants hospitalized only for apnoea and with any high-risk conditions for respiratory failure (congenital heart disease, neurologic disorders, and immunodeficiency), those qualified for palivizumab prophylaxis, and those with incomplete clinical data.
Infants were discharged 24 h after they no longer needed respiratory support and they achieved full enteral feeding again, and they no longer needed intravenous infusion.
The primary outcome was the need for respiratory support (either high-flow nasal cannula, nasal continuous positive airway pressure, or mechanical ventilation).
The secondary outcome was the length of hospital stay (days).
Full text: Click here
Publication 2023
Air Movements Apnea Birth Weight Bronchiolitis Congenital Heart Defects Gender Gestational Age Immunologic Deficiency Syndromes Infant Infant, Newborn Intravenous Infusion Lethargy Mechanical Ventilation Nasal Cannula Nasal Continuous Positive Airway Pressure Nervous System Disorder Oxygen Saturation Palivizumab Patients Respiration Disorders Respiratory Rate Respiratory Syncytial Virus Infections Skin Pigmentation

Top products related to «Bronchiolitis»

Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Switzerland, Belgium, United Kingdom, Germany, Italy, France, Spain, Netherlands, Australia, Canada, Austria, Sweden, Gabon, New Zealand
Penicillin/streptomycin is a solution containing two antibiotics commonly used in cell culture and molecular biology applications. The solution provides a way to prevent bacterial contamination in laboratory settings.
Sourced in United States, United Kingdom, Austria, Denmark
Stata 15 is a comprehensive, integrated statistical software package that provides a wide range of tools for data analysis, management, and visualization. It is designed to facilitate efficient and effective statistical analysis, catering to the needs of researchers, analysts, and professionals across various fields.
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
Sourced in Japan, United States, Germany, Canada, United Kingdom, Spain, Australia, Belgium, Hungary, Switzerland, Denmark, France, China
The BX41 is an upright microscope designed for routine laboratory applications. It features a high-intensity LED illumination system and a sturdy, ergonomic design.
Sourced in United States, Japan
The AIDR 3D is a high-performance 3D printer designed for laboratory and research applications. It utilizes advanced additive manufacturing technology to create accurate and detailed three-dimensional objects. The AIDR 3D offers precise control over the printing process, ensuring consistent and reliable results.
Sourced in Italy
MSwab is a laboratory sample collection device designed for the safe and efficient collection of specimens. It features a sterile swab and a transport medium vial to preserve the sample during transportation to the laboratory for analysis.

More about "Bronchiolitis"

Bronchiolitis is a common respiratory condition primarily affecting young children, characterized by inflammation and obstruction of the small airways, or bronchioles.
This ailment is often caused by viral infections, such as respiratory syncytial virus (RSV), and can lead to symptoms like coughing, wheezing, and difficulty breathing.
Proper diagnosis and management of Bronchiolitis are crucial for ensuring the best possible outcomes for patients.
Synonyms for Bronchiolitis include small airway disease, infantile bronchiolitis, and viral bronchiolitis.
Related terms encompass respiratory distress syndrome, asthma, and lower respiratory tract infections.
Abbreviations used in the context of Bronchiolitis include RSV (respiratory syncytial virus) and LRTI (lower respiratory tract infection).
Key subtopics in the study of Bronchiolitis include epidemiology, pathogenesis, clinical presentation, diagnosis (e.g., using SAS 9.4, Stata 15, or the BX41 microscope), treatment (e.g., Penicillin/streptomycin), and prevention (e.g., AIDR 3D, MSwab).
Researchers can leverage innovative tools like PubCompare.ai to optimize their Bronchiolitis studies, locate relevant protocols, and compare findings to enhance reproducibility and accuracy.
Whether you're a clinician, researcher, or healthcare professional, understanding the nuances of Bronchiolitis is essential for providing the best possible care and advancing medical knowledge in this important field.